Subcutaneous Delivery Patents: Who Leads, Where the Gaps Are 2026
Subcutaneous Delivery and Hyaluronidase Patents: Mapping Who Owns the Claim Space
29.5% of the field sits with five assignees. 2,567 of 8,714 records in scope belong to the top five, a concentration that narrows where a new entrant can file cleanly. Filings ran from 454 in 2017 to a peak of 535 in 2019, then held roughly flat through the recent complete years — 439 in 2021 versus 444 in 2024, a +1% span. The 2025 and 2026 figures (49 for the partial latest year) understate true filing activity because publication typically lags filing by around 18 months.
- 1IONIS PHARMACEUTICALS INC9.7%
- 2REGENERON PHARMACEUTICALS INC6.0%
- 3FIVE PRIME THERAPEUTICS INC5.1%
- 4SANOFI BIOTECH SAS4.5%
- 5SANOFI SA(FR)4.1%
See the full subcutaneous delivery and hyaluronidase analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
How concentrated is the subcutaneous delivery and hyaluronidase patent field?
It is moderately concentrated but not closed. The top five assignees together hold 2,567 of the 8,714 records in scope, which is 29.5% of the field, and the single leader accounts for 843 records. Below the top ten, filing density drops off quickly — tenth place sits at 174 records — which leaves a long tail of entities with smaller, more specific filings. A new entrant is more likely to find open space in formulation niches than in the broad hyaluronidase-coformulation approach itself.
Is filing activity in this space growing or slowing down?
Filing volume has been essentially flat across the most recent complete years, moving from 439 records in 2021 to 444 in 2024, a rise of about 1%. The peak year so far was 2019 at 535 records. Figures for 2025 and 2026 look lower, but that reflects the roughly 18-month lag between filing and publication rather than an actual slowdown, so those years should not be used to call a trend.
What technology areas dominate the IPC classification of these patents?
Medicinal preparation claims under A61K appear on 79.2% of the 8,714 records, making it by far the most common classification, followed by therapeutic activity claims (A61P) at 48.8% and peptide and protein chemistry (C07K) at 33.7%. Genetic engineering (C12N) and nucleic acid chemistry (C07H) form smaller secondary layers. Because a single record can carry several IPC codes, these percentages add up to more than 100% and should each be read against the full 8,714-record base rather than against each other.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Subcutaneous Delivery and Hyaluronidase covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.